Defining the roles of ATR activators ETAA1 and TopB1 in the alternative lengthening of telomeres pathway

Autor: Lock, Ying Jie

Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism utilized by a subset of cancers to promote replicative immortality. The ALT mechanism is driven by increased replication stress and persistent DNA damage response signal

Externí odkaz: https://hdl.handle.net/2144/43770

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Identification of a novel gene fusion in ALT positive osteosarcoma.

Autor: Mason-Osann E; Departments of Pharmacology and Experimental Therapeutics, and Medicine Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA., Dai A; BU Bioinformatics Hub, Boston University, Boston, MA 02118, USA., Floro J; Departments of Pharmacology and Experimental Therapeutics, and Medicine Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA., Lock YJ; Departments of Pharmacology and Experimental Therapeutics, and Medicine Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA., Reiss M; Departments of Pharmacology and Experimental Therapeutics, and Medicine Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA., Gali H; Departments of Pharmacology and Experimental Therapeutics, and Medicine Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA., Matschulat A; Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA., Labadorf A; BU Bioinformatics Hub, Boston University, Boston, MA 02118, USA., Flynn RL; Departments of Pharmacology and Experimental Therapeutics, and Medicine Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA.

Publikováno v: Oncotarget [Oncotarget] 2018 Aug 28; Vol. 9 (67), pp. 32868-32880. Date of Electronic Publication: 2018 Aug 28 (Print Publication: 2018).